AI주식인사이트AI Stock Insight
C

오름테라퓨틱

475830KOSDAQ기초 의약물질 제조업

44.8 / 100

Reference Date: 2026-06-10

Financial Score7.5 / 40
News Sentiment21.3 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 26.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Orm Therapeutics is a clinical-stage biotech company developing antibody-based targeted protein degradation (TPD²®) therapies to treat cancer. Its key candidates, ORM-5029 and ORM-1153, target HER2-positive breast cancer and hematologic malignancies, with ORM-5029 in Phase 1 trials and ORM-1153 preparing for IND submission in 2026. TPD² combines ADC technology to deliver protein degraders selectively to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy.

Number of Employees

21people

Average Salary

174.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 27.714.0Point
PBR
10.27Industry Average 1.740.0Point

5.9x industry avg (risky)

ROE
-33.22Industry Average -6.033.5Point

5.5x industry avg (excellent)

Debt Ratio
17.44Industry Average 6.620.0Point

2.6x industry avg (risky)

Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼99.9% (1-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼521.0% (1-year basis)

ROE Trend
0.0 / 4

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 62,500Won52-week high 143,70052-week low 17,180
1-month return0.0Point

1m -26.90% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-06-09
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
  • Neutral분기보고서 (2026.03)2026-05-15